Avitus Orthopaedics Gains FDA Clearance for Expanded Indications of Avitus Bone Harvester
The Avitus Bone Harvester is now indicated for debridement and capture of diseased cancellous bone such as osteomyelitis and tumors....
Apr 13, 2021,
Orthobiologics
ORTHOFLASH 
First Case with TheraFuse DBF Fiber Bag in Spinal Surgery
TheraCell's TheraFuze DBF Fiber Bag is an allograft alternative to the resorbable polymer mesh bag products currently on the market....
Apr 06, 2021,
Biocomposites Launches Biocomposites Companion App
The app puts user information in the hands of healthcare professionals to support STIMULAN and genex at point of use....
Mar 30, 2021,
Seikagaku Granted Marketing Approval for JOYCLU Joint Function Improvement Injection
JOYCLU, a combination of hyaluronic acid and an anti-inflammatory drug, is approved for manufacture and marketing in Japan....
Mar 23, 2021,
FDA Clinical Hold Removed for Histogen Trial in Knee Regeneration
Histogen can proceed with a Phase I/II clinical trial examining human extracellular matrix plus microfracture to regenerate hyaline cartilage....
Mar 15, 2021,
First Patients Enrolled in Bioventus MOTYS Trial for Knee OA
The trial is examining MOTYS placental tissue particulate in the treatment of osteoarthritis of the knee....
Mar 11, 2021,
Creative Medical Begins Recruitment of StemSpine Clinical Sites
StemSpine is the company's regenerative stem cell procedure for the treatment of degenerative disc disease....
Mar 10, 2021,
TissueTech to Commence Study on Facet Joint Osteoarthritis Pain
The study is investigating Cryopreserved Amniotic Membrane and Cryopreserved Umbilical Cord for pain relief and functional improvement....
Mar 09, 2021,
TheraCell Launches TheraFuze DBF Fiber Bag Solution For Graft Containment In Spinal Surgery
The TheraFuze DBF Fiber Bag is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures. ...
Mar 02, 2021,
Locate Bio’s Chondro3 Graft Granted FDA Breakthrough Device Designation
The biomimetic graft for osteochondral lesions is the company's second Breakthrough Device designation granted in 2021....
Feb 25, 2021,
Loading new posts...
No more posts
